Reliability of death certificates in prostate cancer patients
Reliability of death certificates in prostate cancer patients
复制标题
DOI：
10.1080/00365590802078583
复制
发表时间：
2008-01-01
影响因子：
--
通讯作者：
Varenhorst, Eberhard
中科院分区：
文献类型：
--
作者：
Fall, Katja;Stromberg, Fredrik;Varenhorst, Eberhard
目标。目的评价前列腺癌患者死因诊断的可靠性。材料和方法。将从瑞典死亡登记处获得的死亡证明信息与东南部地区基于人口的瑞典区域前列腺癌登记处系统审查的医疗记录进行比较。总共有5675名患者在1987年至1999年间被诊断出患有前列腺癌，并在2003年1月1日之前死亡。结果。在官方死亡证明中被归类为死于前列腺癌的前列腺癌病例的比例比在回顾记录中高3%[0.03，95%可信区间(CI)0.02至0.04]。官方死因与回顾数据的总体符合率为86%(95%可信区间为85%至87%)。在有局限性疾病的男性(88%，95%可信区间87至89%)、死亡时年龄在60岁或以下的男性(96%，95%可信区间93至100%)或接受过根治治疗的男性(91%，95%可信区间88至95%)中观察到较高的准确率。这项研究表明，瑞典前列腺癌患者的官方死因统计数据的可靠性相对较高。结论。从死亡证明中获得的死亡率数据可能有助于评估大规模前列腺癌干预计划，特别是在患有局部疾病的年轻患者中。
Objective. To evaluate the reliability of cause-of-death diagnoses among prostate cancer patients. Material and methods. Information from death certificates obtained from the Swedish Death Register was compared with systematically reviewed medical records from the population-based Swedish Regional Prostate Cancer Register, South-East Region. In total, 5675 patients were included who had been diagnosed with prostate cancer between 1987 and 1999 and who had died before 1 January 2003. Results. The proportion of prostate cancer cases classified as having died from prostate cancer was 3% higher in the official death certificates than in the reviewed records [0.03, 95% confidence interval (CI) 0.02 to 0.04]. Overall agreement between the official cause of death and the reviewed data was 86% (95% CI 85 to 87%). A higher accuracy was observed among men with localized disease (88%, 95% CI 87 to 89%), aged 60 years or younger at death (96%, 95% CI 93 to 100%), or who had undergone curative treatment (91%, 95% CI 88 to 95%). This study indicates a relatively high reliability of official cause-of-death statistics of prostate cancer patients in Sweden. Conclusion. Mortality data obtained from death certificates may be useful in the evaluation of large-scale prostate cancer intervention programmes, especially among younger patients with localized disease.